Skip to main content

09-22-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Psychologic resilience tied to glycemic control after type 1 diabetes diagnosis

Author: Eleanor McDermid


medwireNews: Researchers find psychologic resilience to be predictive of glycated hemoglobin (HbA1c) levels in the 3 years after type 1 diabetes diagnosis.

Moreover, low resilience was associated with poorer mental health status (measured on the SF-12 quality of life questionnaire) at baseline and with its deterioration over the first 2 years after diabetes diagnosis in people with type 1 or type 2 diabetes.

Simon Brackley (National Institute for Health Research, Exeter, UK) presented the findings at the 58th EASD Annual Meeting in Stockholm, Sweden.

“The implications of this is that we could target these individuals with low resilience and either give them targeted diabetes team support, consider trying to improve their resilience, or give more targeted mental health support, which might improve both their mental health and their glycemic outcomes,” he said.

The 1267 study participants came from the StartRight cohort, a multicenter prospective cohort study of adults with a recent diabetes diagnosis, which included the Connor-Davidson Resilience Scale (CD-RISC) as a secondary outcome measure.

Among the 462 people diagnosed with type 1 diabetes, each 10-point increase in baseline resilience was significantly associated with an average 4.1 mmol/mol lower HbA1c during the 3 years of follow-up, after adjusting for age, sex, BMI and baseline HbA1c.

This relationship appeared strongest in those with severe insulin deficiency (urinary C-peptide: creatinine ratio <0.2 nmol/mmol), with each 10-point increase in resilience associated with HbA1c being 6.6 mmol/mol lower during follow-up, compared with 3.7 mmol/mol lower for those who were not severely insulin deficient.

“I’m not suggesting we use this as a prediction model, but if we were to consider the population averages, we see a difference of approximately 10 mmol/mol, which is definitely a clinically significant effect size,” said Brackley.

By contrast, there was no association between resilience and glycemic outcomes in the 573 people diagnosed with type 2 diabetes. Each 10-point increase in resilience was associated with 1.1 mmol/mol lower HbA1c during follow-up, which was not statistically significant (p=0.06).

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

EASD Annual Meeting; Stockholm, Sweden: Sept 19–23, 2022


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video